Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Run-Ning Zhao, Song Fan, Ju-Guang Han & Guang Liu. (2015) Molecular dynamics study of segment peptides of Bax, Bim, and Mcl-1 BH3 domain of the apoptosis-regulating proteins bound to the anti-apoptotic Mcl-1 protein. Journal of Biomolecular Structure and Dynamics 33:5, pages 1067-1081.
Read now
Read now
Articles from other publishers (20)
Ekhlass Uddin, Raisul Islam, Ashrafuzzaman, Nur Amin Bitu, Md. Saddam Hossain, ABM Nazmul Islam, Ali Asraf, Faruk Hossen, Ranjan K Mohapatra & Md. Kudrat-E-Zahan. (2021) Potential Drugs for the Treatment of COVID-19: Synthesis, Brief History and Application. Current Drug Research Reviews 13:3, pages 184-202.
Crossref
Crossref
Maruti B. Yadav & Yeon Tae Jeong. (2021) A one-pot ring-closure and ring-opening sequence for the cascade synthesis of dihydrofurofurans and functionalized furans. Organic & Biomolecular Chemistry 19:34, pages 7409-7419.
Crossref
Crossref
Karthika Paul, Jaswanth Gowda BH, SJ Shankar & D Narasimha Reddy. (2021) Development and validation of simplified RP-HPLC method for quantification of Darunavir in commercial tablets. Materials Today: Proceedings 47, pages 4155-4161.
Crossref
Crossref
Nitin B. Charbe, Flavia C. Zacconi, Nikhil Amnerkar, B. Ramesh, Murtaza M. Tambuwala & Emilio Clementi. (2019) Bio-analytical Assay Methods used in Therapeutic Drug Monitoring of Antiretroviral Drugs-A Review. Current Drug Therapy 14:1, pages 16-57.
Crossref
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
687
736
.
Silvia Baroncelli, Paola Villani, Clementina M. Galluzzo, Albertina Cavalli, Anna Volpe, Daniela Francisci, Angela Vivarelli, Federica Sozio, Sara Tedeschi, Oscar Cirioni, Laura Sighinolfi, Maria Cusato, Maria F. Pirillo, Liliana E. Weimer, Vincenzo Fragola, Giustino Parruti, Mario Regazzi & Marco Floridia. (2013) Interindividual and Intra-Individual Variabilities of Darunavir and Ritonavir Plasma Trough Concentrations in Multidrug Experienced HIV Patients Receiving Salvage Regimens. Therapeutic Drug Monitoring 35:6, pages 785-790.
Crossref
Crossref
M.C. Serrano Vicente, H. Navarro Aznárez, P. Carrera Lasfuentes, M.R. Abad Sazatornil, O. Horna Oreja & M.J. Rabanaque Hernández. (2012) Efectividad y seguridad de la terapia de rescate en pacientes VIH. Farmacia Hospitalaria 36:4, pages 187-193.
Crossref
Crossref
Garima Kumari & Ramendra K. Singh. (2012) Highly Active Antiretroviral Therapy for treatment of HIV/AIDS patients: Current status and future prospects and the Indian scenario. HIV & AIDS Review 11:1, pages 5-14.
Crossref
Crossref
J. Zhang, L. Zhu, M. Stonier, J. Coumbis, X. Xu, Y. Wu, D. Arikan, A. Farajallah & R. Bertz. (2011) Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir. Journal of Antimicrobial Chemotherapy 66:9, pages 2075-2082.
Crossref
Crossref
Melvin J. Yu. (2011) Natural Product-Like Virtual Libraries: Recursive Atom-Based Enumeration. Journal of Chemical Information and Modeling 51:3, pages 541-557.
Crossref
Crossref
Hitomi Nakamura, Noriaki Hosoya, Michiko Koga, Takashi Odawara, Tadashi Kikuchi, Ai Kawana-Tachikawa, Toshiyuki Miura, Naoko Miyazaki, Tomohiko Koibuchi, Takeshi Fujii & Aikichi Iwamoto. (2011) Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir. Journal of Infection and Chemotherapy 17:1, pages 105-110.
Crossref
Crossref
Sidonie Lambert-Niclot, Gilles Peytavin, Claudine Duvivier, Catherine Poirot, Michèle Algarte-Genin, Sophie Pakianather, Jean-Luc Meynard, Marc-Antoine Valantin, Jean-Michel Molina, Philippe Flandre, Christine Katlama, Vincent Calvez & Anne-Geneviève Marcelin. (2010) Low Frequency of Intermittent HIV-1 Semen Excretion in Patients Treated with Darunavir-Ritonavir at 600/100 Milligrams Twice a Day plus Two Nucleoside Reverse Transcriptase Inhibitors or Monotherapy. Antimicrobial Agents and Chemotherapy 54:11, pages 4910-4913.
Crossref
Crossref
Youcef Mehellou & Erik De Clercq. (2009) Twenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go?. Journal of Medicinal Chemistry 53:2, pages 521-538.
Crossref
Crossref
A. ViganòV. ManfrediniC. MameliV. GiacometG.V. Zuccotti. (2010) Pharmacotherapy Update: Treatment of HIV Infection with Darunavir. Clinical Medicine Insights: Therapeutics 2, pages CMT.S1101.
Crossref
Crossref
Kevin C. Brown, Sunita Paul & Angela D.M. Kashuba. (2009) Drug Interactions with New and Investigational Antiretrovirals. Clinical Pharmacokinetics 48:4, pages 211-241.
Crossref
Crossref
Tingjun Hou, Wei Zhang, Jian Wang & Wei Wang. (2009) Predicting drug resistance of the HIV-1 protease using molecular interaction energy components. Proteins: Structure, Function, and Bioinformatics 74:4, pages 837-846.
Crossref
Crossref
O Sued, J Lattner, A Gun, P Patterson, L Abusamra, C Cesar, V Fink, A Krolewiecki & P Cahn. (2008) Use of darunavir and enfuvirtide in a pregnant woman. International Journal of STD & AIDS 19:12, pages 866-867.
Crossref
Crossref
Christoph Boesecke & David A Cooper. (2008) Toxicity of HIV protease inhibitors: clinical considerations. Current Opinion in HIV and AIDS 3:6, pages 653-659.
Crossref
Crossref
Juan Pasquau Liaño & Carmen Hidalgo Tenorio. (2008) Características químicas, mecanismo de acción y actividad antiviral de darunavir. Enfermedades Infecciosas y Microbiología Clínica 26, pages 3-9.
Crossref
Crossref
Christine Katlama. (2008) The POWER and TITAN trials: darunavir/ritonavir in the management of HIV-infected patients. Future HIV Therapy 2:3, pages 229-245.
Crossref
Crossref